Sparsentan Recruiting Phase 3 Trials for Immunoglobulin A Nephropathy Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03762850A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy